Scalper1 News
Biotech Halozyme Therapeutics (HALO) jumped as much as 18% Tuesday morning, nearly touching an all-time high, a day after the company beat Q2 estimates and provided an update on its pipeline. But shares reversed to close lower. Late Monday, Halozyme reported revenue of $43.4 million, up 136% from the year-earlier quarter and $18 million more than analysts expected. More than half the revenue came from a $23 million milestone payment from AbbVie Scalper1 News
Scalper1 News